Table 1.
Clinical characteristics of 203 patients with chronic hepatitis B with nucleos(t) ide analogue-induced HBeAg seroclearance
| Variables | Values |
|---|---|
| Cohort number (n) | 203 |
| Male: Female (%) | 128:75 (63.1:36.9) |
| Mean age at baseline, year (range) | 37 (18–82) |
| Mean age at HBeAg seroclearance, year (range) | 40 (20–84) |
| Mean age at last follow-up, year (range) | 44 (24–85) |
| Follow-up duration, year (range) | 5 (2–11) |
| First-line antiviral therapy (%) | 173 (85.2) |
| Entecavir: Tenofovir: Entecavir plus Tenofovir (%) | 152:49:2 (74.9:24.1:1.0) |
| At time of HBeAg seroclearance | |
| Liver cirrhosis (%) | 75 (36.9) |
| Diabetes (%) | 33 (16.3) |
| Mean HBV DNA†, log10 IU/mL (range) | 1.3 (negative-4.9) |
| Mean ALT*, IU/L (range) | 25 (14–110) |
| Mean albumin, g/dL (range) | 4.2 (3.0–5.1) |
| Mean bilirubin, mg/dL (range) | 1.0 (0.8–2.5) |
| Mean platelet count, 103/μL (range) | 183 (130–427) |
NOTE. Values are given as mean (range)
*The upper limit of normal ALT level is less than 40 IU/L.
†The lower limit of detection for HBV DNA is 12 IU/mL
Abbreviations: ALT alanine aminotransferase; HBV hepatitis B virus